STRM.BIO Secures Funding for Revolutionary Gene Therapy
STRM.BIO, a leading start-up in biotechnology, has received a significant boost by securing a contract from the Advanced Research Projects Agency for Health (ARPA-H). This prestigious award is part of ARPA-H's program that focuses on the Engineering of Immune Cells Inside the Body. The project aims to advance the development of their innovative megakaryocyte-derived extracellular vesicle (MV) delivery platform for in vivo immune cell engineering.
Funding Details and Future Implications
The awarded contract includes impressive funding of up to $8.4 million to initiate the project. This funding will catalyze STRM.BIO's mission, enhancing its capabilities in utilizing extracellular vesicles for effective cell and gene therapy. Such funding is pivotal for the advancement of medical technologies aimed at precision and safety in therapeutic applications.
Statements from Leadership
CEO Michael Luther, Ph.D., emphasized the importance of this opportunity, stating, "This award marks an important milestone for STRM.BIO in our mission to unlock the potential of extracellular vesicles for in vivo cell and gene therapy. Funding from ARPA-H provides us an extraordinary opportunity to accelerate the development of our MV platform and genetic medicines pipeline." Luther pointed out that this initiative allows the delivery of complex genetic materials directly to the bone marrow.
Collaborative Efforts to Drive Innovation
STRM.BIO is set to lead the project by collaborating with renowned partners such as Ginkgo Bioworks and the University of British Columbia (UBC). This partnership aims to optimize the design and biology of self-amplifying RNA (saRNA) in the development of CAR-T therapeutics, leveraging each partner's expertise to enhance the efficacy of in vivo immune cell engineering techniques.
Transformative Potential of ARPA-H Funding
David Raiser, Ph.D., COO of STRM.BIO, remarked on the transformative nature of ARPA-H funding, stating, "This funding from ARPA-H is transformative for high-impact projects like this. We're fortunate to collaborate with partners who share our vision for a new generation of in vivo cell and gene therapies enabled by innovative, non-viral delivery technologies." This collective effort is expected to push forward the boundaries of therapeutic innovation.
Future Perspectives on Gene Therapy
As the development progresses, STRM.BIO anticipates that insights gained from this initiative will significantly enhance the capabilities of their MV platform. The objective is to open new avenues for the in vivo engineering of immune and hematopoietic cells, directly addressing unmet medical needs in the gene therapy landscape.
About STRM.BIO
Based in Massachusetts, STRM.BIO focuses on pioneering a non-viral, cell-derived delivery modality that ensures safe and targeted in vivo delivery of genetic therapies. The company’s innovative MV technology seeks to overcome the hurdles posed by traditional viral and synthetic delivery systems, thus unlocking new treatment possibilities in gene editing and immune cell engineering.
Frequently Asked Questions
What is the focus of STRM.BIO's recent ARPA-H contract?
STRM.BIO's ARPA-H contract focuses on advancing their megakaryocyte-derived extracellular vesicle delivery platform for in vivo immune cell engineering and gene therapy.
How much funding did STRM.BIO receive?
STRM.BIO has been awarded up to $8.4 million in funding from ARPA-H for the initial phase of their project.
Who are STRM.BIO's key partners in this initiative?
Key partners include Ginkgo Bioworks, the University of British Columbia, and Advanced Bioprocess Services.
What are the expected outcomes of this collaboration?
The collaboration aims to enhance the development of CAR-T therapeutics and optimize the delivery of complex genetic cargo to targeted cells.
Where is STRM.BIO headquartered?
STRM.BIO is headquartered in Massachusetts, focusing on innovative solutions for gene therapy.
